Industry Sessions

​​Thursday, March 30, 2017

​09:15 – 11:15
Hall A
THE CONTINUUM OF AD: WHAT ARE THE IMPLICATIONS FOR THE PATH TO 2025?

Symposium Organized by: LILLY

CHAIR: JEFFREY CUMMINGS, USA

09:15  WELCOME AND INTRODUCTION
Jeffrey Cummings, USA

09:25  THE BIOMARKER CONTINUUM OF AD
Bruno Dubois, France

09:45  THE CLINICAL CONTINUUM OF AD
Roy Jones, UK

10:05  IMPLICATIONS OF THE AD CONTINUUM FOR THE PATH TO 2025
Jeffrey Cummings, USA

10:30  DISCUSSION PANEL AND Q&A
All

11:05  CLOSING REMARKS
Jeffrey Cummings, USA


11:45 – 13:30
Hall A
THE EMERGING PICTURE OF EARLY ALZHEIMER'S DISEASE: A CASE STUDY FOR DIAGNOSIS

Symposium Organized by: BIOGEN​

CHAIRS: Peter Dal-Bianco, Austria and Ron Petersen, USA

11:45       INTRODUCTION AND WELCOME
Ron Petersen, USA

11:50       FORGETTING BUT NOT FORGOTTEN
Peter Dal-​Bianco, Austria

CASE PRESENTATION PART # 1

12:00       CURRENT RESEARCH IN ACTION: COGNITIVE ASSESSMENTS
Lutz Frölich, Germany

CASE PRESENTATION: PART #2

12:30       CURRENT RESEARCH IN ACTION: IMAGING AND BIOMARKERS
Chris Rowe, Australia

CASE PRESENTATION: PART #3

12:55       CURRENT RESEARCH IN ACTION: PATIENT MANAGEMENT
José-Luis Molinuevo, Spain

13:20       PANEL DISCUSSION

13:30       SUMMARY AND CLOSE
Ron Petersen, USA​


17:15 – 19:15
Hall B
SAFINAMIDE:  A NEW THERAPEUTIC OPTION FOR PD PATIENTS NOT STABILISED ON LEVODOPA

Symposium Organized by: ZAMBON

CHAIR: Werner Poewe, Austria

17:15       INTRODUCTION AND WELCOME
Werner Poewe, Austria

17:20       LEVODOPA: THE MAINSTAY FOR MANAGING MOTOR SYMPTOMS
Angelo Antonini, Italy

17:45       UPDATE ON PD PATHOPHYSIOLOGY – NON-DOPAMINE PATHWAYS AS THERAPEUTIC TARGETS
Susan Fox, Canada

18:10       SAFINAMIDE – A UNIQUE TREATMENT TARGETING BOTH DOPAMINERGIC AND NON-DOPAMINERGIC SYSTEMS
Paolo Barone, Italy

18:35       QUESTION & ANSWERS SESSION


19:25 – 21:25
Hall A
TARGETING BACE INHIBITION IN EARLY ALZHEIMER'S DISEASE

Symposium Organized by: EISAI

CHAIR: Jeffrey Cummings, USA

19:25     AMYLOID AND ALZHEIMER'S: DECREASING RISK AND INCREASING SUCCESS
Jeffrey Cummings, USA

19:45     BACE INHIBITION: THE SCIENCE AND THE STUDIES
Howard Feldman, USA

20:05     THE IMPORTANCE OF EARLY TREATMENT
Stephen Salloway, USA

20:25     SUMMARY
Jeffrey Cummings, USA

20:45     PANEL DISCUSSION Q&A  

 

Friday, March 31, 2017


09:15 – 11:15
Hall A
TAKING THE DIRECT PATH: THE CASE FOR D1 AGONISM IN PARKINSON'S DISEASE

​Symposium Organized by: PFIZER INC

CHAIR: Olivier Rascol, France

9:15        INTRODUCTION AND OPENING REMARKS
Olivier Rascol, France

9:25        PHARMACOLOGY OF DOPAMINE RECEPTORS
Richard Mailman, USA

9:55        DEVELOPMENT AND CHARACTERIZATION OF A NOVEL FAMILY OF D1/5 RECEPTOR LIGANDS
David Gray, USA

10:25      RATIONALE FOR TARGETING D1/5 RECEPTORS IN PARKINSON'S DISEASE
Erwan Bezard, France

​10:55      PANEL DISCUSSION AND Q/A​


11:45 – 13:25
Hall A
EXTENDING THE AMYLOID CASCADE: REASONS TO STILL BELIEVE

Symposium Organized by: ROCHE

CHAIR: Philip Scheltens, The Netherlands

11:45     WELCOME AND INTRODUCTION
Philip Scheltens, The Netherlands

11:50     IS THE AMYLOID CASCADE HYPOTHESIS STILL VALID AS A TARGET FOR DRUG THERAPY?
Dennis Selkoe, USA

12:00     THE AMYLOID-TAU RELATIONSHIP: DO WE KNOW ENOUGH TO IMPACT THE TREATMENT TARGETS?
Brad Hyman, USA

12:10     TREM2 AND MICROGLIAL ACTIVITY – NOVEL THERAPEUTIC TARGETS IN THE AMYLOID CASCADE?
Christian Haass, Germany

12:20     THE EMERGING TREATMENT PARADIGM: HOW DOES RECENT PHASE 3 CLINICAL TRIAL DATA IMPACT THE FIELD?
Philip Scheltens, The Netherlands

12:30      PANEL DEBATE / DISCUSSION

12:55     GENERAL Q & A 


17:15 – 19:15
Hall B
BEYOND THE BASAL GANGLIA: ALPHA-SYNUCLEIN PATHOLOGY AND NON-MOTOR MANIFESTATIONS IN PARKINSON'S DISEASE​

Symposium Organized by:​ PROTHENA and ROCHE

MODERATOR:
Wolfgang Oertel, Germany

17:15      WELCOME AND INTRODUCTION
Wolfgang Oertel, Germany

17:20     EARLY SYMPTOMS OF PARKINSON'S DISEASE: THE PATIENT'S PERSPECTIVE
Tom Isaacs, United Kingdom

17: 35     SPREADING OF PROTEIN AGGREGATES IN ANIMAL MODELS OF ALPHA-SYNUCLEINOPATHIES
Patrik Brundin, USA

17.55     ALPHA-SYNUCLEIN PATHOLOGY IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEM
Thomas Beach, USA

18.15      NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE
Brit Mollenhauer, Germany

18.35     PRODROMAL PARKINSON'S DISEASE
Ronald Postuma, Canada

18.55      NOVEL ENDPOINTS FOR MEASURING NON-MOTOR SYMPTOMS IN PD
Jamie Eberling, USA

 

Saturday, APRIL 1, 2017

09:15 – 11:15
Hall B
FRONTIERS IN DIAGNOSTICS AND THERAPY OF HUMAN TAUOPATHIES

Symposium Organized by: Axon Neuroscience

CHAIRS:  Markus Otto, Germany, and Jonathan Rohrer, Uk

09:15     ACTIVE TAU VACCINE AADVAC1 - FROM ALZHEIMER'S DISEASE CLINICAL TRIAL TO OTHER TAUOPATHY STUDIES
Matej Ondrus ,Slovakia

09:35     THE LONGITUDINAL CHANGES IN FTD
Markus Otto, Germany

09:55     ARE WE READY FOR DISEASE MODIFYING THERAPIES OF PSP?
Günter Höglinger, Germany

10:15     DEVELOPING BIOMARKERS FOR FTD
Jonathan Rohrer,UK

10:35     MULTIMORBIDITY OF THE AGEING BRAIN; IMPLICATIONS FOR CLINICOPATHOLOGICAL CORRELATIVE STUDIES AND CLINICAL TRIALS
Johannes Attems , UK

10:55     THE COMMON TARGET FOR AD AND FTD THERAPY
Norbert Zilka ,Slovakia



17:15 – 19:15
Hall B
DLB SYMPOSIUM

Symposium Organized by:​ AXOVANT SCIENCES

CHAIRS: Ian McKeith, UK and James Galvin, USA

17:15    DIAGNOSIS AND MANAGEMENT OF DLB: FOURTH REPORT OF THE DLB CONSORTIUM
Ian McKeith, UK  

17:30    DIFFERENTIAL DIAGNOSIS
James Galvin, USA

17:45 PHENOTYPIC VARIATION IN LEWY BODY DEMENTIA
Bradley Boeve, USA

18:00  THE ROLE OF POST-TRANSLATIONAL MODIFICATIONS ON ALPHA-SYNUCLEIN BIOLOGY AND PATHOBIOLOGY
Tiago Outeiro, Germany    

18:15 CHOLINERGIC DIFFERENCES BETWEEN AD AND PD (LBD)
James Leverenz, USA

18:30 THERAPEUTICS FOR DLB
John Paul Taylor, UK

18:45 THE GENETIC BASIS OF DEMENTIA WITH LEWY BODIES
Jose Bras, UK

19:00  MODELING OF DLB AS INFORMED BY GENETIC LEADS
Michael Schlossmacher, Canada



AD/PD™ Facebook
AD/PD™ Twitter
AD/PD™ Network

Keep Me Updated